Ginkgo Bioworks Revenue and Competitors
Estimated Revenue & Valuation
- Ginkgo Bioworks's estimated annual revenue is currently $197.4M per year.
- Ginkgo Bioworks received $275.0M in venture funding in December 2017.
- Ginkgo Bioworks's estimated revenue per employee is $224,318
- Ginkgo Bioworks's total funding is $1.6B.
- Ginkgo Bioworks's current valuation is $8.6B. (January 2022}
Employee Data
- Ginkgo Bioworks has 880 Employees.
- Ginkgo Bioworks grew their employee count by 27% last year.
Ginkgo Bioworks Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $356.8M | 1205 | 32% | $1.8B | $1.5B |
#2 | $19.6M | 563 | -31% | $974.1M | $562.2M |
#3 | $3.2M | 32 | N/A | $20M | N/A |
What Is Ginkgo Bioworks?
The Organism Company Ginkgo Bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. Our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Robotics,Wind Power
$1.6B
Total Funding
880
Number of Employees
$197.4M
Revenue (est)
27%
Employee Growth %
$8.6B
Valuation
Y Combinator
Accelerator
Ginkgo Bioworks News
BOSTON, Nov. 8, 2021 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2021, on Monday, November 15, 202 ...
BOSTON, Nov. 11, 2021 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells ...
BOSTON, Nov. 24, 2021 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences: Piper Sandler Annual Healthcare Conference on Tuesday, November 30, 2021 J ...
Motif, a Ginkgo Bioworks spinoff that exited stealth in February with $90 million in Series A, raised $27.5 million in an extended round of funding ...
Motif is based on research from Ginkgo Bioworks, a synthetic biology company that engineers microbes to produce compounds used in a wide ...
Motif Ingredients, the company launched by synthetic biology firm Ginkgo Bioworks, announced today it has raised an additional $27.5 million ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $197.4M | 880 | 27% | $1.6B |
#2 | $332.6M | 880 | 6% | N/A |
#3 | N/A | 900 | 12% | N/A |
#4 | $189.4M | 902 | 7% | N/A |
#5 | $183.3M | 903 | N/A | N/A |
Ginkgo Bioworks Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-19 | $9.0M | A | Multiple | Article |
| 2015-07-24 | $45.0M | B | Article | |
| 2016-06-09 | $100.0M | C | Multiple | Article |
| 2017-12-15 | $275.0M | D | General Atlantic | Article |
